Loading...
Tenofovir is a key component in two of the four first-line HIV treatment regimens recommended by the WHO, and its use is rapidly increasing. By the end of 2010, 19% of patients on first-line therapy in low- and middle-income countries were receiving tenofovir-containing regimens (up from 8% just 1 year prior). A substantial proportion of these patients are women of childbearing age, raising concerns about the effects of tenofovir on pregnancy and infant outcomes, particularly bone and renal health.
To address this issue, researchers evaluated data from women who became pregnant while receiving antiretroviral therapy (ART) as part of the DART study in Africa. A total of 382 pregnancies occurred; in 29%, the women received no tenofovir, wherea…